News & Events about Minerva Neurosciences Inc.
StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV Get Rating) in a research note released on Wednesday morning. The brokerage issued a sell rating on the biopharmaceutical companys stock. Separately, HC Wainwright reaffirmed a neutral rating and set a $8.00 price objective...
Globe Newswire
3 months ago
Company to Host Conference Call Today at 8:30 a.m. ETBURLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc.(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business ...
Globe Newswire
3 months ago
Management to Host Conference CallBURLINGTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc.(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release ...
Globe Newswire
5 months ago
BURLINGTON, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that, following the Type A meeting held on November 30...
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates PR Newswire PALM BEACH, FL, Nov. 14, 2022 PALM BEACH, FL, Nov. 14, 2022...